文献速递血液透析通路

GLP-1受体激动剂治疗与动静脉瘘结局改善相关

Glucagon-like peptide-1 receptor agonist therapy is associated with improved outcomes of arteriovenous fistulae.
PubMed 文献 · J Vasc Surg · 2026-02-05

该多中心回顾性队列研究基于TriNetX网络,纳入37,694例2017年1月至2022年10月行开放AVF创建的ESKD患者,经倾向评分1:1匹配后比较新启用GLP-1RA者与对照的1年结局,发现GLP-1RA与瘘管血栓、狭窄、感染、透析导管干预和开放翻修风险降低相关,长期生存改善。

要点

  • GLP-1RA与AVF血栓、狭窄、感染风险降低相关。
  • GLP-1RA与透析导管干预和开放翻修风险降低相关。
  • 保护效应在男性及HbA1c≥7%、BMI≥35或eGFR≤30者中更明显。

核心结论

  • 在行AVF创建的ESKD患者中,新启用GLP-1RA与更少的通路并发症、更少的透析导管干预及长期生存改善相关。

研究设计与样本

  • 多中心回顾性队列研究,使用TriNetX研究网络。
  • 纳入37,694例2017年1月至2022年10月行开放AVF创建且随访至少1年的ESKD患者。
  • 新启用GLP-1RA者与未使用者按倾向评分1:1匹配,匹配后形成1239对匹配良好的配对。

关键数值与推荐

  • 保护效应在男性及HbA1c≥7%、BMI≥35 kg/m2或eGFR≤30 mL/min/1.73 m2者中更明显。

临床怎么用

  • 对合并2型糖尿病和肾病的ESKD患者,启用GLP-1RA可能有助于减少AVF通路并发症及导管干预。
  • 在男性及HbA1c≥7%、BMI≥35 kg/m2或eGFR≤30 mL/min/1.73 m2的患者中,GLP-1RA的保护效应可能更明显。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Arteriovenous fistulae (AVF) are necessary for hemodialysis in patients with end-stage kidney disease (ESKD), but are frequently complicated by thrombosis, stenosis, and need for revision. Glucagon-like peptide-1 receptor agonists (GLP-1RA) are increasingly used in patients with type 2 diabetes and kidney disease, with recent evidence of both cardiovascular and renoprotective effects, yet their influence on AVF outcomes is unknown. The aim of this study was to investigate the impact of GLP-1RA on AVF outcomes in patients with ESKD. METHODS: We conducted a multicenter, retrospective cohort study using the TriNetX Research Network. This included 37,694 patients with ESKD who underwent open AVF creation from January 2017 to October 2022, with a minimum of 1 year of follow-up. Patients started on new a GLP-1RA therapy were matched 1:1 with non-GLP-1RA controls using propensity scores accounting for patient demographics, comorbidities, medication history, and diagnoses. The primary outcomes included the risk of fistula thrombosis, stenosis, infection, percutaneous angioplasty, and open revision over 1 year. Secondary outcomes included dialysis catheter intervention, major adverse cardiovascular events, and all-cause mortality. Cox proportional hazards regression and survival analyses were performed. RESULTS: After matching, 1239 well-matched pairs were created. Patients started on GLP-1RA therapy were associated with a lower risk of fistula thrombosis (HR, 0.77; 95% CI, 0.60-0.97; log-rank P = .03), stenosis (HR, 0.82; 95% CI, 0.71-0.95; log-rank P = .01), infection (HR, 0.61; 95% CI, 0.41-0.90; log-rank P = .01), dialysis catheter intervention (HR, 0.63; 95% CI, 0.53-0.76; log-rank P < .01), and open revision (HR, 0.57; 95% CI, 0.47-0.69; log-rank P < .01) at one year. No significant effects were observed for percutaneous angioplasty (HR, 0.88; 95% CI, 0.75-1.05; log-rank P = .15), major adverse cardiovascular events (HR, 0.99; 95% CI, 0.88-1.11; log-rank P = .86), or all-cause mortality (HR, 0.79; 95% CI, 0.59-1.05; log-rank P = .10. The protective effects of GLP-1RA were more prominent among male patients and in those with a hemoglobin A1C of ≥7%, body mass index of ≥35 kg/m2, or estimated glomerular filtration rate of ≤30 mL/min/1.73 m2. These protective effects were also seen as early as 12 weeks after AVF creation and persisted through three years, at which point GLP-1RA use was associated with improved survival (HR, 0.81; 95% CI, 0.68-0.96; log-rank P = .02). CONCLUSIONS: In patients with ESKD undergoing AVF creation, new GLP-1RA therapy was associated with fewer access complications, fewer dialysis catheter interventions, and improved long-term survival. These findings suggest that GLP-1RA use may promote a favorable environment after access creation, allowing AVF to mature.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Hsu J, Ho B, Sayed R, et al. Glucagon-like peptide-1 receptor agonist therapy is associated with improved outcomes of arteriovenous fistulae. J Vasc Surg. 2026. PMID: 41654037. doi:10.1016/j.jvs.2026.02.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。